{"id":"bupropion-citalopram","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Seizure risk (bupropion)"},{"rate":null,"effect":"QT prolongation (citalopram)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the central nervous system. Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability. Together, this combination targets multiple monoamine neurotransmitter systems to treat depression and potentially improve mood and motivation.","oneSentence":"This combination blocks the reuptake of norepinephrine and dopamine (bupropion) and serotonin (citalopram) to increase their availability in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:40:39.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT00958633","phase":"PHASE3","title":"Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2010-11","conditions":"Bipolar I Disorder","enrollment":237},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":""},{"nctId":"NCT04446039","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-04","conditions":"Major Depression","enrollment":370212},{"nctId":"NCT06675851","phase":"PHASE4","title":"Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2022-12-01","conditions":"Major Depressive Disorder (MDD)","enrollment":120},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT05543122","phase":"","title":"Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2022-03-09","conditions":"Breast Feeding","enrollment":39},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT04352101","phase":"PHASE4","title":"Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-09-23","conditions":"Major Depression","enrollment":18},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT02458690","phase":"PHASE2","title":"eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-07","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":216},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT03993457","phase":"PHASE4","title":"Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-07-23","conditions":"Depression","enrollment":18},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT02624102","phase":"PHASE3","title":"Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression","status":"COMPLETED","sponsor":"Hemanny, Curt, M.D.","startDate":"2015-09","conditions":"Major Depressive Disorder","enrollment":76},{"nctId":"NCT02332291","phase":"PHASE4","title":"Connectivity Affecting the Antidepressant REsponse Study","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-04","conditions":"Major Depressive Disorder","enrollment":95},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT02755194","phase":"","title":"\"Drugs in Lactation\" Analysis Consortium","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-09","conditions":"Lactation","enrollment":68},{"nctId":"NCT00080158","phase":"PHASE2, PHASE3","title":"Treatment of Adolescent Suicide Attempters (TASA)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-03","conditions":"Depression, Suicide, Attempted","enrollment":120},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT02191397","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-02-10","conditions":"Depressive Disorder, Major","enrollment":534},{"nctId":"NCT03623711","phase":"EARLY_PHASE1","title":"A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression","status":"UNKNOWN","sponsor":"Yuqi Cheng","startDate":"2018-08-01","conditions":"Major Depressive Disorder, Depression, Unipolar","enrollment":200},{"nctId":"NCT01715805","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-11-15","conditions":"Major Depressive Disorder","enrollment":1022},{"nctId":"NCT01838876","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-29","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT03927950","phase":"PHASE4","title":"Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment","status":"COMPLETED","sponsor":"University of Tartu","startDate":"2007-01","conditions":"Major Depression","enrollment":135},{"nctId":"NCT03278938","phase":"PHASE4","title":"Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2012-06-29","conditions":"Depressive Illness","enrollment":""},{"nctId":"NCT01469377","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12-15","conditions":"Major Depressive Disorder","enrollment":819},{"nctId":"NCT00404755","phase":"PHASE4","title":"Dichotic Listening as a Predictor of Medication Response in Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2006-07","conditions":"Major Depressive Disorder, Dysthymia","enrollment":17},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00057551","phase":"PHASE4","title":"Research Evaluating the Value of Augmenting Medication With Psychotherapy","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2003-04","conditions":"Depression, Depressive Disorder","enrollment":491},{"nctId":"NCT02178696","phase":"PHASE4","title":"Predictors of Antidepressant Response","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-01","conditions":"Depression","enrollment":44},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT00519428","phase":"PHASE4","title":"Does Dual Therapy Hasten Antidepressant Response?","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-08","conditions":"Major Depressive Disorder","enrollment":245},{"nctId":"NCT01032018","phase":"PHASE1, PHASE2","title":"Comparison of Depression Interventions After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Columbia University","startDate":"2010-01","conditions":"Acute Coronary Syndrome, Depression","enrollment":150},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01944657","phase":"NA","title":"Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study","status":"WITHDRAWN","sponsor":"Sheppard Pratt Health System","startDate":"2013-09","conditions":"1. Major Depressive Disorder","enrollment":""},{"nctId":"NCT01716221","phase":"PHASE4","title":"An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-10","conditions":"Friedreich Ataxia","enrollment":1},{"nctId":"NCT00817011","phase":"NA","title":"Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2006-04","conditions":"Depression, Antidepressant Drug Adverse Reaction","enrollment":1000},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT00129467","phase":"NA","title":"Methylphenidate for Depressed Cancer Patients Receiving Palliative Care","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-02","conditions":"Depression, Palliative Care, Cancer","enrollment":47},{"nctId":"NCT00590863","phase":"PHASE4","title":"Combining Medications to Enhance Depression Outcomes","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-03","conditions":"Major Depressive Disorder","enrollment":665},{"nctId":"NCT01541475","phase":"PHASE4","title":"Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Ewha Womans University","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT01896349","phase":"NA","title":"Interpersonal Psychotherapy for Treatment Resistant Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-04","conditions":"Treatment Resistant Depression","enrollment":74},{"nctId":"NCT00612807","phase":"PHASE1, PHASE2","title":"Treatment of Mood and Marriage Study (TOMMS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-07","conditions":"Major Depressive Disorder, Partner Relational Disorder (V61.10)","enrollment":42},{"nctId":"NCT00917059","phase":"PHASE4","title":"Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-05","conditions":"Depression","enrollment":172},{"nctId":"NCT01764867","phase":"PHASE4","title":"Algorithm Guided Treatment Strategies for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2012-06","conditions":"Major Depressive Disorder","enrollment":1080},{"nctId":"NCT00296777","phase":"PHASE4","title":"Treatment of Depression Following Multiple Brain Tests","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-12","conditions":"Major Depression, Dysthymia","enrollment":28},{"nctId":"NCT00296712","phase":"PHASE4","title":"Are Two Antidepressants a Good Initial Treatment for Depression?","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2005-02","conditions":"Major Depression, Dysthymia, Depression NOS","enrollment":55},{"nctId":"NCT00289523","phase":"","title":"EEG Biomarkers for Predicting Response to Antidepressant Therapy","status":"COMPLETED","sponsor":"Medtronic - MITG","startDate":"2006-01","conditions":"Major Depressive Disorder","enrollment":375},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT01369290","phase":"","title":"Electroencephalography (EEG) Signal Processing","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2009-10","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT00051272","phase":"PHASE3","title":"Effects Of Antidepressants On Sexual Functioning In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Major Depressive Disorder (MDD)","enrollment":425},{"nctId":"NCT00351910","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":494},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT00051259","phase":"PHASE3","title":"Effects of Antidepressants on Sexual Functioning","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Major Depressive Disorder (MDD)","enrollment":420},{"nctId":"NCT00296933","phase":"PHASE3","title":"Memory Functioning and Antidepressant Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2005-12","conditions":"Depression, Major Depressive Disorder","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":307,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"bupropion & Citalopram","genericName":"bupropion & Citalopram","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion is a small molecule that inhibits the sodium-dependent dopamine transporter, and it has been studied in clinical trials for conditions such as Major Depressive Disorder and Friedreich Ataxia. Citalopram, on the other hand, is also a small molecule inhibitor, but its molecular target is not specified in the provided facts, and it has been studied in clinical trials for conditions such as Major Depressive Disorder and Dysthymia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}